I am also going to attend and will hope to get some questions answered. We all have been looking to explain why we sit here in the 5 dollar range given the information we know. I am just not buying the dilution effects of Congate nor the ongoing financing needs or the lack of complete data or the failure of dndn. We have been given a substantial taste of absolutely incredible,unheard of results from direct(not to mention all we know about -L). Yet we have no analyst coverage, no excitement from anyone outside of retail investors, and have been unable to get favorable Financing in the US. It seems that LP has refused to cooperate with the US financial institutions and thus has made the company a target for attack.
Now, with the recent financing, something significant has changed. LP clearly has enough information to move from a position of weakness to a position of strength, yet she still sought financing in Europe and not the US. It is clear LP does not have the support of US financial institutions. However, she does have the cooperation from the FDA and the researchers(minus Buzz). Additionally, I am not sure if she is choosing to raise funds from quarter to quarter because she wants to or she is without a choice? Why not get financing, if you have strong data, for the year? Is it because she can't or because it's not going to be needed as the HE commences?
I don't know the answer to these questions but I can say for sure that they have delivered enough encouraging data to drive wild speculation yet no one is blinking an eye. And I don't care about the warrants. The holders can make money on the appreciation of those warrants. So the dilution or the conversion of those are meaningless if there is substantial interest in this stock. I suspect those who say the complete data will be the only thing to move this stock are correct. Unfortunately we don't get to enjoy the excitement of speculative success like all other biotechs and because of that may be unnecessarily diluted. All we know, from dissecting the congate deal, is LP has an incredible plan for commercialization, cancer patients, and herself, but we don't know what she has in store for us. Although at this point i'm not overly concerned because it will be hard for the success of this company to not have serious spill over to its common shareholders.